Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the use of avelumab, a new agent that became available for patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Avelumab: New Agent Available for Merkel Cell Carcinoma
